0      0

AONN+ Annual 2020


SAT05 - Product Theater 7 | Insights on Managing Patients with CLL and MCL on a Selective BTK Inhibitor Therapy (non-CE) Presentation by AstraZeneca


Nov 7, 2020 10:00am ‐ Nov 7, 2020 11:00am

Description

The “Insights on Managing Patients with CLL and MCL on a Selective BTK Inhibitor Therapy” deck presents a general overview of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) epidemiology and disease pathogenesis along with a review of the efficacy and safety profile of a selective BTK inhibitor. To empower patients and care teams to effectively manage patients on treatment with a selective BTK inhibitor and encourage adherence, detailed information on best practices for adverse event management.

HCP Website

CLL Dosing Guide

Request A Representative

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content